VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide

Article summary

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent ("LOI") with Missionpharma A/S, a Danish global leader in the sale and...